Cover Image

Propiedad intelectual y acceso a medicamentos:el caso de lopinavir/ritonavir en Guatemala

El impacto de la protección de la propiedad intelectual de los productos farmacéuticos en el acceso a medicamentos en los países de ingreso bajo y medio ha sido motivo de debate a nivel mundial desde finales del siglo XX...

Saved in:

Bibliographic Details
Main Authors:	Luis Pablo Méndez-Alburez (Author), Alejandro Cerón (Author)
Format:	Book
Published:	Instituto Nacional de Salud Pública, 2016-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Factors associated with chronic kidney disease of non-traditional causes among children in Guatemala
by: Alejandro Cerón, et al.
Published: (2021)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
by: Ashish Chandwani, et al.
Published: (2008)

355 Lopinavir/ritonavir treatment in paediatric patients with covid-19
by: P Ip, et al.
Published: (2021)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018)

Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis
by: Bahman Amani, et al.
Published: (2021)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
by: Christiana Smith, et al.
Published: (2016)

Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials
by: Tejas K. Patel, et al.
Published: (2021)

Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir
by: Yin, Guosheng, et al.
Published: (2020)

Melatonin and alpha lipoic acid restore electrolytes and kidney morphology of lopinavir/ritonavir-treated rats
by: Elias Adikwu, et al.
Published: (2020)

Amorphous solid dispersion formation via solvent granulation - A case study with ritonavir and lopinavir
by: Niraj S. Trasi, et al.
Published: (2019)

Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection
by: Irin Tanaudommongkon, et al.
Published: (2021)

Influence of traditional Chinese medicines on the in vivo metabolism of lopinavir/ritonavir based on UHPLC-MS/MS analysis
by: Linlin Li, et al.
Published: (2022)

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
by: Yu. Yu. Kiselev, et al.
Published: (2020)

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy
by: Linhu Ye, et al.
Published: (2021)

A novel validated UPLC method for quantitation of lopinavir and ritonavir in bulk drug and pharmaceutical formulation with its impurities
by: Gnana Deepika Killi, et al.
Published: (2014)

Salud pública y propiedad intelectual en Cuba: mapa conceptual
by: Beatriz García Delgado, et al.

Stevia. Conocimiento, propiedad intelectual y acumulación de capital
by: Lautaro Zubeldia Brenner
Published: (2022)

Stevia. Conocimiento, propiedad intelectual y acumulación de capital
by: Lautaro Zubeldia Brenner
Published: (2022)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
by: Yin-Qiu Huang, et al.
Published: (2020)

Functional Role of P-Glycoprotein and Binding Protein Effect on the Placental Transfer of Lopinavir/Ritonavir in the Ex Vivo Human Perfusion Model
by: Pierre-Francois Ceccaldi, et al.
Published: (2009)

Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
by: Vincenzo Russo, et al.
Published: (2020)

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children
by: Nils von Hentig, et al.
Published: (2021)

Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria
by: Sikiru Olatunji Usman, et al.
Published: (2020)

No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison
by: Roberta Gagliardini, et al.
Published: (2021)

Medicamentos esenciales y Acuerdo sobre los ADPIC: colisión entre el derecho a la salud y el derecho de propiedad intelectual
by: Raúl Allard Soto
Published: (2015)

Mapa conceptual sobre salud pública y propiedad intelectual en Cuba: actualización 2020
by: Beatriz García Delgado, et al.
Published: (2020)

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19
by: Mario Karolyi, et al.
Published: (2021)

Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis
by: Audrey Monnin, et al.
Published: (2021)

Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements Acceso a antirretrovirales genéricos: desigualdad, derecho de propiedad intelectual y acuerdos comerciales internacionales
by: Arachu Castro, et al.
Published: (2007)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
by: M. Karolyi, et al.
Published: (2022)

Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
by: Bin Su, et al.
Published: (2019)

miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir
by: Elena Bresciani, et al.
Published: (2019)

Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México
by: Molina-Salazar Raúl E., et al.
Published: (1998)

Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México
by: Raúl E. Molina-Salazar, et al.

Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México
by: Raúl E. Molina-Salazar, et al.

PROTECCIÓN DE LA PROPIEDAD INTELECTUAL DE LA MEDICINA TRADICIONAL DE LOS PUEBLOS INDÍGENAS: ESPECIAL REFERENCIA AL CASO PERUANO
by: Doly Rocio Jurado Cerrón
Published: (2021)

Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations
by: Yinqiu Huang, et al.
Published: (2018)

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week
by: Henri Gautier Ouedraogo, et al.
Published: (2020)

Mapa conceptual en salud y propiedad intelectual en Centroamérica y la República Dominicana
by: Beatriz M. García Delgado, et al.
Published: (2019)

La propiedad intelectual en la salud pública y las agendas nacionales de salud
by: Eliana Martínez-Herrera, et al.
Published: (2009)